Trial Profile

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAS 303 (Primary)
Indications Urinary-Stress-Incontinence
Focus Therapeutic Use
Sponsors Taiho Pharmaceutical

Most Recent Events

10 Sep 2022 Primary endpoint (The percent change in the average SUI episode frequency per 24 hours) has been met according to the Results presented at the 52nd Annual Meeting of the International Continence Society.
10 Sep 2022 Results assessing the efficacy of Tas-303 in Female Patients with Stress Urinary Incontinence presented at the 52nd Annual Meeting of the International Continence Society
08 Feb 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com